Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 902 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 902 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $43,223.84. Following the transaction, the senior vice president now directly owns 3,524 shares in the company, valued at approximately $168,870.08. This represents a 20.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Stock Up 2.0 %

Mirum Pharmaceuticals stock traded up $0.95 during midday trading on Monday, hitting $48.48. 1,319,360 shares of the stock were exchanged, compared to its average volume of 540,941. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $49.40. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The business’s 50-day moving average price is $43.76 and its 200-day moving average price is $41.61. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -24.00 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s revenue was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.57) EPS. On average, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Amalgamated Bank raised its stake in shares of Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares during the period. R Squared Ltd purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $69,000. Avanza Fonder AB bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at approximately $189,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $213,000.

Analysts Set New Price Targets

A number of research analysts recently weighed in on MIRM shares. Leerink Partners upped their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Citigroup upped their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.